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Adipocyte PU.1 knockout promotes 
insulin sensitivity in HFD-fed obese 
mice
Denise E. Lackey1, Felipe C. G. Reis  1, Roi isaac1, Rizaldy C. Zapata1, Dalila El Ouarrat1, 
Yun Sok Lee  1, Gautam Bandyopadhyay1, Jachelle M. Ofrecio1, Da Young oh  2 & 
Olivia Osborn1
Insulin resistance is a key feature of obesity and type 2 diabetes. PU.1 is a master transcription factor 
predominantly expressed in macrophages but after HFD feeding PU.1 expression is also significantly 
increased in adipocytes. We generated adipocyte specific PU.1 knockout mice using adiponectin cre to 
investigate the role of PU.1 in adipocyte biology, insulin and glucose homeostasis. In HFD-fed obese 
mice systemic glucose tolerance and insulin sensitivity were improved in PU.1 AKO mice and clamp 
studies indicated improvements in both adipose and liver insulin sensitivity. At the level of adipose 
tissue, macrophage infiltration and inflammation was decreased and glucose uptake was increased 
in PU.1 AKO mice compared with controls. While PU.1 deletion in adipocytes did not affect the gene 
expression of PPARg itself, we observed increased expression of PPARg target genes in eWAT from HFD 
fed PU.1 AKO mice compared with controls. Furthermore, we observed decreased phosphorylation at 
serine 273 in PU.1 AKO mice compared with fl/fl controls, indicating that PPARg is more active when 
PU.1 expression is reduced in adipocytes. Therefore, in obesity the increased expression of PU.1 in 
adipocytes modifies the adipocyte PPARg cistrome resulting in impaired glucose tolerance and insulin 
sensitivity.
Insulin resistance is a characteristic defect in the majority of patients with type 2 diabetes mellitus (T2DM)1. 
Obesity is the major cause of insulin resistance in man and the increasing global obesity rates are tightly coupled 
to the parallel increase in global rates of T2DM2. Adipose tissue plays an important role in maintaining metabolic 
function and it is well described that chronic adipose tissue inflammation is an important cause of systemic insu-
lin resistance.
PPARg is a master regulator of adipogenesis, and regulates the expression of many genes associated with 
metabolic pathways3,4. Indeed, PPARg expression in other cell types, such as fibroblasts and myoblasts, results 
in an adipocyte-like phenotype5. In contrast, the signal independent transcription factor PU.1, encoded by the 
gene Pu1 or Spi1, is a key regulator of the hematopoietic lineage, especially of antigen presenting cells including 
macrophages, dendritic cells, and B cells. Binding of PU.1 to its recognition motifs facilitates chromatin opening 
and, together with DNA methyltransferases and other transcription factors, allows for signal-dependent tran-
scription factor binding and transcription initiation6,7. PU.1 is also a potent re-programming factor where ectopic 
expression of PU.1 induces monocyte, macrophage, or dendritic cell morphology and function in fibroblasts and 
neural stem cells8–11.
More recently, it has been discovered that PU.1 is expressed by adipocytes, with increased expression in the 
obese state, particularly in the gonadal WAT depot12,13. PU.1 overexpression in 3T3-L1 preadipocytes inhibits 
the adipocyte differentiation process, partially through repression of C/EBPα and β transcriptional activity12,13. 
Conversely, PU.1 knockdown in differentiated 3T3-L1 or OP9-K adipocytes leads to increased insulin signaling 
with decreased pro-inflammatory cytokine expression and increased adipogenesis13,14.
Due to its role as a lineage-determining transcription factor, PU.1 has also been studied in the context of 
PPARg cistrome programming. For example, PU.1 overexpression caused a 75% loss of PPARg binding to tar-
get gene promoters with a global decrease in PPARg binding strength15. These studies suggest that increased 
1Department of Medicine, University of California San Diego, 9500 Gilman Drive, La Jolla, CA, 92093, USA. 
2Touchstone Diabetes Center, Department of Internal Medicine, University of Texas Southwestern Medical Center, 
5323 Harry Hines Blvd, Dallas, Texas, USA. Correspondence and requests for materials should be addressed to O.O. 
(email: oosborn@ucsd.edu)
Received: 8 February 2019
Accepted: 26 September 2019
Published: xx xx xxxx
open
2Scientific RepoRtS |         (2019) 9:14779  | https://doi.org/10.1038/s41598-019-51196-8
www.nature.com/scientificreportswww.nature.com/scientificreports/
adipocyte PU.1 expression in obesity could promote the proinflammatory, insulin resistant state. However, the 
role of PU.1 in adipocytes is poorly defined in vivo in the context of obesity. In the current studies, we gen-
erated adipocyte-specific PU.1 knockout (PU.1 AKO) mice to assess its role in adipogenesis, adipose tissue 
inflammation, and insulin resistance in the obese state. We show that PU.1 AKO mice fed high fat diet (HFD) 
have improved glucose tolerance and insulin sensitivity, with decreased adipose tissue inflammation, increased 
PPARg-target gene expression and decreased hepatic steatosis.
Results
Obesity results in increased PU.1 expression. PU.1 is highly expressed in adipose tissue with the stro-
mal vascular cells (SVCs) largely contributing to the overall expression under lean conditions (Fig. 1A). However, 
in adipose tissue from HFD-fed obese mice the adipocyte levels of PU.1 are significantly induced in both SVCs 
and adipocytes (Fig. 1A). PU.1 is also expressed in the liver but expression levels are unchanged after HFD feeding 
in both hepatocytes and non-parenchymal cells (NPCs) (Fig. 1A). Treatment of differentiated 3T3-L1 adipocytes 
with TNF-alpha, a potent pro-inflammatory stimulus16, significantly increases PU.1 expression compared with 
control treated cells (Fig. 1B).
PU.1 AKO tissue panel and genotyping. To investigate the role of adipocyte PU.1 in obesity-related 
insulin resistance, we generated adipocyte-specific PU.1 knockout (PU.1 AKO) mice by using adiponectin 
(Adipoq) Cre-mediated excision of PU.1 floxed alleles (Pu1 fl/fl; Adipoq-Cre+/−). Floxed Pu1 mice that do not 
express Cre-recombinase were used as controls, referred to as fl/fl (Fig. S1A,B). There was no significant difference 
in glucose tolerance between WT and adiponectin cre mice (Supplemental Fig. 2C). Under HFD conditions, PU.1 
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Figure 1. Pu1 expression. (A) Relative Pu1 expression in various cell types from normal chow (NC) and 
high fat diet (HFD)-fed mice. (B) Relative Pu1 gene expression in 3T3-L1 adipocytes harvested 7 d post-
differentiation, treated with or without TNFa for 48 h. (C) Relative Pu1 expression in various cell types/tissues 
in fl/fl and PU.1 AKO mice after 14 wk HFD, normalized to adipocyte fl/fl expression. (D) Quantification 
of western blot detection of PU.1 in eWAT from fl/fl and PU.1 AKO mice, relative to HSP90 expression (see 
Supplemental Fig. 1C). Values are fold induction of gene expression normalized to the housekeeping gene Rplp0 
and expressed as mean ± SEM, n = 5 per group, *p < 0.05 comparing two groups using a t-test.
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AKO mice show ~63% decreased PU.1 mRNA expression in the eWAT adipocytes compared with fl/fl controls. 
Pu1 expression is unchanged in SVC cells and other insulin responsive metabolic tissues (liver and skeletal mus-
cle) and the immunologic tissue (spleen) in PU.1 AKO compared with WT mice (Fig. 1C). Western blotting of 
the eWAT adipose tissue confirmed significant reduction of PU.1 protein expression in PU.1 AKO mice compared 
with fl/fl controls (Fig. 1D and Supplemental Fig. 1C).
PU.1 AKO results in improved glucose tolerance and insulin sensitivity. To investigate the role of 
adipocyte PU.1 expression in the context of obesity and insulin resistance PU.1 AKO and fl/fl control mice were 
fed 60% HFD for up to 14 weeks, starting at 10 weeks of age. Obese, HFD fed PU.1 AKO mice showed improved 
glucose tolerance (Fig. 2A,B) with lower basal insulin levels compared to fl/fl control mice (Fig. 2C) and improved 
insulin sensitivity (Fig. 2D). Both fl/fl and PU.1 AKO mice become equally obese after consuming HFD (Fig. 2E). 
Lean PU.1 AKO mice did not show any differences in glucose or insulin tolerance compared to lean fl/fl mice, 
likely due to the observation that adipocytes from lean mice have very low levels of PU.1 (Fig. S2A,B). To quantify 
the tissue-specific responses to insulin, hyperinsulinemic-euglycemic clamp studies were performed in HFD fed 
PU.1 AKO and fl/fl controls. The amount of exogenous glucose required to maintain euglycemia (the glucose 
infusion rate (GIR)) was greater in PU.1 AKO mice, indicating improved insulin sensitivity in PU.1 AKO mice 
(Fig. 2F). The increased insulin sensitivity in PU.1 AKO mice was primarily due to an increased hepatic response 
to insulin, resulting in greater suppression of hepatic glucose production (HGP) during the clamp studies 
(Fig. 2G,H). There was also a trend (p = 0.09) towards greater suppression of free fatty acid (FFA) secretion from 
adipose tissue in PU.1 AKO mice (Fig. 2I). Basal and insulin-stimulated glucose disposal rates (GDR) were similar 
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Figure 2. Improved glucose tolerance and insulin sensitivity in PU.1 AKO mice. (A) Glucose tolerance 
test (GTT) (B) Area under curve (AUC) of GTT. (C) Fasting insulin after 10 wks of HFD, and (D) insulin 
tolerance test after 11 wks of HFD in fl/fl and PU.1 AKO. (E) Body weight, (F) glucose infusion rate (GIR), 
(G) basal and clamp hepatic glucose production (HGP), (H) percent HGP suppression, (I) percent free fatty 
acid (FFA) suppression, (J) basal glucose disposal rate (GDR), and (K) insulin stimulated (IS)-GDR during 
hyperinsulinemic-euglycemic clamp after 12 wks HFD. Insulin-stimulated AKT phosphorylation in (L) liver, 
(M) eWAT, and (N) skeletal muscle 14 wk after HFD. (O) Representative H&E staining of paraffin embedded 
liver sections. (P) Triglyceride (TG) concentration in livers from HFD-fed fl/fl and PU.1 AKO mice. Expression 
of genes associated with pro-inflammation (Q) and anti-inflammation (R) in livers from HFD-fed fl/fl and PU.1 
AKO mice. Values are expressed as mean ± SEM, n = 7–10 per group, *p < 0.05 by t-test.
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in WT and PU.1 AKO mice suggested there was no difference in muscle insulin sensitivity (Fig. 2J,K). We also 
conducted acute in vivo insulin stimulation studies and found a similar pattern as observed in the clamp studies 
with significantly increased pAKT activation in the liver, and a trend (p = 0.1) for improvement in eWAT in PU.1 
AKO mice compared to fl/fl mice, with (Fig. 2L,M). There was no difference in pAKT levels in insulin-stimulated 
muscle from PU.1 AKO or WT mice (Fig. 2N). Histologic images of hemotoxylin and eosin stained liver sections 
indicate less fat accumulation in livers from HFD-fed PU.1 AKO mice with fewer ballooned hepatocytes (Fig. 2O) 
compared with fl/fl controls. In addition, liver triglyceride concentrations were also significantly decreased in 
PU.1 AKO mice (Fig. 2P). Gene expression of pro-inflammatory mediators was decreased in livers from obese 
PU.1 AKO mice compared to fl/fl mice, including the M1-like macrophage surface marker Cd11c, and chemokine 
Mcp1 (Fig. 2Q). In addition, the M2-like macrophage-associated anti-inflammatory mediator Arg1 was signifi-
cantly increased in the livers of PU.1 AKO HFD mice compared to fl/fl controls (Fig. 2R).
PU.1 AKO results in increased expression of adipogenic genes. In previous in vitro based exper-
iments PU.1 has been shown to inhibit adipogenesis12,17,18. In agreement with these studies we also observed 
significantly greater levels of the adipogenic genes Fasn, Acaca, Adipsin, Srebp1c and Scd1 in adipose tissue from 
PU.1 KO mice compared with fl/fl controls (Fig. 3A). Comparison of eWAT adipocyte size from HFD fed fl/fl 
and PU.1 AKO mice showed no significant difference in cell size with average cell diameter of 64 ± 26.8 μm in 
PU.1 KO mice vs 68 ± 31.6 μm vs. in fl/fl mice (Fig. 3B,C). Epididymal adipose tissue mass was slightly decreased 
in PU.1 KO mice (Fig. 3D) but this was not statistically significant (p = 0.12). To determine how PU.1 function-
ally affects adipocyte insulin sensitivity, we measured glucose transport in primary adipocytes. Cells from PU.1 
AKO HFD mice are more insulin sensitive than adipocytes from fl/fl HFD mice, as demonstrated by greater 
insulin-stimulated glucose uptake (Fig. 3E). We also observed decreased concentrations of the circulating adi-
pokines leptin and PAI-1 in PU.1 AKO mice while levels of adiponectin, resistin, FFA, and triglycerides were the 
same between the two groups (Fig. 3F–K). Together these data indicate that increased adipocyte expression of 
PU.1 in obese mice plays a role in the development of obesity-induced insulin resistance.
PU.1 KO results in decreased adipose tissue inflammation. We next studied the contribution of 
PU.1 expression on the inflammatory state of the adipose tissue in HFD-fed obese PU.1 AKO and fl/fl mice. We 
found decreased macrophage infiltration in eWAT in PU.1 AKO mice, as displayed in F4/80-stained immuno-
histochemistry sections, compared with fl/fl HFD-fed mice (Fig. 4A). FACs analyses of the eWAT SVCs revealed 
lower levels of M1-like/proinflammatory cells (F4/80+ CD11b+ CD11c+) and increased levels of M2-like/less 
inflammatory macrophages (F4/80+ CD11b+ CD11c−) in PU.1 AKO mice compared to fl/fl mice (Fig. 4B,C). In 
light of the decreased number of M1-like macrophages observed in PU.1 AKO eWAT compared with control and 
the decreased local production of the chemokine leukotriene LTB4 (Fig. 4D) we examined in vivo macrophage 
tracking in these mice (Fig. 4E–G). When PKH26-labeled WT peripheral blood monocytes were injected into 
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Figure 3. PU.1 negatively affects adipocyte metabolism. (A) Relative mRNA expression of adipogenic-
associated genes in eWAT from fl/fl and PU.1 AKO mice after 14 wk HFD feeding and (B). Adipocyte diameter 
was quantified and sorted by bins with Lowess curve fitting in both f/f mice (B) and PU.I AKO mice (C). 
(D) Epididymal adipose weight. Glucose uptake, as a percent of basal 3H-2-deoxy-D-glucose uptake, in (E). 
Cultured primary adipocytes from eWAT from HFD-fed fl/fl and PU.1 AKO mice. Plasma concentrations of 
(F). leptin, (G). Total PAI-1, (H). Adiponectin, (I). Resistin, (J). Free fatty acids (FFA), and (K). Triglycerides 
(TG) in fl/fl and PU.1 AKO mice after 14 wk HFD feeding. Values are expressed as mean ± SEM, *p < 0.05 
by t-test. All groups are significantly different from each other for each gene analyzed in B by 2-way ANOVA 
followed by Tukey’s post-hoc test. N = 10–14 per group in (A) and (F–K), n = 6–8 per group in (B–E).
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fl/fl and PU.1 AKO HFD mice we found decreased PKH26-labeled cells in eWAT of PU.1 AKO recipient mice 
compared with WT (Fig. 4E) as well as decreased PKH26+ M1-like polarized cells (F4/80+ CD11b+ CD11c+) 
(Fig. 4F,G). Consistent with these in vivo macrophage tracking results we also observed similar effects in an 
ex vivo chemotaxis assays where conditioned medium (CM) from cultured primary PU.1 AKO HFD adipo-
cytes showed a decreased effect to stimulate chemotaxis of WT IP macrophages than CM from fl/fl HFD adipo-
cytes (Fig. 4H). Analysis of gene expression in eWAT from PU.1 AKO HFD mice showed significantly decreased 
adipocyte expression of inflammation-associated genes, including F4/80, Cd11c, Tnfa and decreased Flap 
(5-lipoxygenase-activating protein), which is an enzyme involved in the biosynthesis of LTB419 (Fig. 4I) and no 
significant changes in inflammatory gene expression in the SVCs (Fig. 4I).
Adipocyte specific ablation of PU.1 affects PPARg. Previous studies have shown that PU.1 globally 
dampens adipocyte PPARg binding15 so we went on to study how the absence of adipocyte PU.1 in obesity affects 
PPARg signaling. While the gene expression levels of transcription factor PPARg are unchanged we observed 
increased expression of PPARg target genes Glut4, Lipe, Pepck, and Plin1 in eWAT from HFD fed PU.1 AKO com-
pared with control fed mice (Fig. 5A). Phosphorylation at PPARg serine 273 is an additional mechanism by which 
PPARg target gene expression can be dysregulated20,21. While Ser-273 phosphorylation does not alter adipogenic 
capacity of PPARg21, target gene expression is dysregulated suggesting differential recruitment of co-regulators 
may drive the differences. In eWAT of PU.1 AKO HFD-fed mice we observed decreased pCDK5 associated with 
decreased phosphorylation of PPARg at serine 273 compared with fl/fl controls, (Fig. 5B,C and Supplemental 
Fig. S3) indicating that PPARg is more active when PU.1 expression is reduced in adipocytes.
Figure 4. PU.1 affects eWAT inflammation in obesity. (A) Paraffin embedded eWAT sections were stained with 
the macrophage marker F4/80 by immunohistochemistry. (B) Flow cytometry gating strategy for analysis of 
F4/80+ ‘M1-like’ (F4/80+ CD11b+ CD11c+) and ‘M2-like (F4/80+ CD11b+ CD11c+) stromal vascular fraction 
from fl/fl and PU.1 AKO eWAT after 14 wk HFD feeding and (C). “M1-like” and “M2-like” macrophages. (D) 
LTB4 local concentration in eWAT in fl/fl and PU.1 AKO HFD fed mice. (E) PKH26 fluorescently-labeled total 
macrophage, (F). M1-like macrophage, and (G). Ratio of ‘M1-like:M2-like’ macrophages tracking in eWAT 
from fl/fl and PU.1 AKO recipient mice after 14 wk HFD feeding. (H) Chemotaxis of WT intraperitoneal-
macrophages (IP-Mac) toward conditioned medium from fl/fl or PU.1 AKO cultured primary eWAT adipocytes 
from HFD mice. Analysis of Inflammation-associated gene expression from (I). Adipocytes or (J). Stromal 
vascular cells from eWAT from HFD fed fl/fl or PU.1 AKO mice. Values are expressed as mean ± SEM, *p < 0.05 
by t-test (D–G), or ANOVA followed by Tukey’s post-hoc test. N = 4–8 per group in (A–C), 10–14 per group in 
(D,H–J) and n = 6–8 per group in (E–G).
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Discussion
PU.1 is also a potent re-programming factor which can confer macrophage-like phenotypic features and functions 
on other differentiated cell types through reprogramming and trans-differentiation8–11. Interestingly adipocyte 
expression of PU.1 increases significantly in the obese state12. In these studies, we generated adipocyte-specific 
PU.1 knockout mice and conducted detailed in vivo and in vitro studies of the role of adipocyte PU.1 in 
obesity-induced inflammation and insulin resistance. We found that adipocyte specific deletion of PU.1 results 
in systemic improvements in glucose tolerance and insulin sensitivity in vivo. Adipocyte specific KO of PU.1 
resulted in decreased liver inflammation, decreased steatosis and significantly improved liver insulin sensitivity 
compared with fl/fl controls, as revealed by both hyperinsulinemic-euglycemic clamp and acute insulin signaling 
studies. It is well established that crosstalk between adipose tissue and liver plays a key role in the maintenance of 
metabolic homeostasis22,23. While PU.1 expression in the liver in unchanged in the PU.1 AKO mice, this suggests 
that signals from the adipose tissue drive changes in inflammation and insulin sensitivity in the liver. We propose 
the reduction in adipose tissue pro-inflammatory cytokines, chemokine, and leukotrienes, are likely to play a 
significant contribution in the resulting in decreased steatosis and improved insulin sensitivity observed in the 
liver of PU.1 AKO mice. Additionally, recent studies have highlighted the key role of adipose tissue macrophage 
derived exosomal miRNAs in the modulation of insulin sensitivity24 that could also be an important signal result-
ing in insulin sensitization in the liver in PU.1 KO mice.
Because of the improved metabolic phenotype in PU.1 AKO HFD mice, we sought to further examine the role 
of PU.1 in adipocytes during obesity. Previous in vitro studies have shown that PU.1 inhibits adipocyte differen-
tiation12,17,18,25,26. In line with these studies we found PU.1 deletion in adipocytes resulted in increased expression 
of adipogenic genes (i.e. Fasn, Acaca). While the in vitro studies show a clear role for PU.1 in adipogenesis, the 
reduction in adipocyte number and size from chronically fed HFD fed PU.1 AKO mice compared with floxed 
controls was very mild and not statistically significant. It is possible that other counter-regulatory genes are 
affected by PU.1 knockout in vivo or perhaps PU.1 expression in adipocytes does not increase immediately in 
response to HFD and the early phases of the PPARg-induced adipocyte differentiation course is not affected.
We conducted an ex-vivo glucose uptake assay in primary adipocytes and found HFD-fed PU.1 AKO adi-
pocytes had significantly greater insulin-stimulated glucose uptake compared with HFD-fed fl/fl control mice. 
These results are consistent with previous in vitro studies showing increased insulin-stimulated glucose uptake in 
3T3-L1 cells with PU.1 knockdown13.
As PU.1 is known as a master regulator of many types of immune cells, we reasoned that it likely plays a role 
in the adipose inflammation associated with obesity. In the obese state adipocytes produce and secrete proin-
flammatory signals that can regulate the recruitment and activation of adipose tissue macrophages27–29. When 
monocytes arrive in adipose tissue they differentiate into macrophages, which, in the inflammatory environment, 
polarize into pro-inflammatory “M1-like” macrophages, further producing more pro-inflammatory cytokines 
and chemokines. Adipocyte specific deletion of PU.1 resulted in reduced expression of pro-inflammatory genes in 
eWAT, decreased number of M1-like macrophages and decreased monocyte tracking to adipose compared with 
fl/fl control mice. In vitro chemotaxis assays confirmed decreased migration towards conditioned medium from 
primary PU.1 AKO adipocytes compared with controls. While levels of the classical chemotactic signal Mcp-1 
were unchanged, levels of the leukotriene LTB4, a potent macrophage chemoattractant produced in adipose tissue 
during obesity30 were significantly lower in adipose tissue from PU.1 AKO mice.
Transcription factors PU.1 and PPARg both play key roles in regulating the expression of many genes associ-
ated with metabolic pathways and cell differentiation in adipose tissue. The PPARg cistrome between adipocytes 
and macrophages is predominantly cell type specific31. However when PU.1 is overexpressed at “macrophage lev-
els” in mature adipocytes, PU.1 globally dampened adipocyte PPARg binding without affecting PPARg15. In agree-
ment with these studies we found PU.1 deletion in adipocytes did not affect the expression of PPARg itself, but 
we observed increased expression of PPARg target genes Glut4, Fabp4, Lipe, Pepck, and Plin1 in eWAT from HFD 
fed PU.1 AKO compared with control fed mice. Furthermore, in eWAT of PU.1 AKO HFD-fed mice we observed 
decreased phosphorylation at serine 273 compared with fl/fl controls, indicating that PPARg is more active when 
PU.1 expression is reduced in adipocytes. Therefore, in obesity the increased expression of PU.1 in adipocytes 
modifies the adipocyte PPARg cistrome. Siersbaek et al. have shown that the PPARg cistrome is different in 
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Figure 5. Adipocyte PU.1 expression negatively affects PPARg activity. PPARg target gene expression in (A). 
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adipocytes differentiated from various adipose depots including eWAT, scWAT, or BAT32. Interestingly in obesity 
PU.1 is predominantly increased in eWAT while largely unchanged in inguinal adipose tissue13 which suggests 
that the expression level of PU.1 in various adipose tissues depots may explain the differences in the PPARg cis-
trome and contribute to metabolic differences between the depots33,34.
In summary, adipocyte specific deletion of PU.1 in HFD-fed obese mice results in improved glucose tolerance 
and insulin sensitivity. In obesity, adipocyte levels of PU.1 are significantly increased and thus further under-
standing the aberrant transcriptional changes mediated by PU.1 may provide important therapeutic targets in the 
treatment of obesity-induced insulin resistance.
Experimental Procedures
Creation of adipocyte-specific PU.1 knockout mice. Mice with PU.1 floxed alleles were provided by 
Dr. David G. Tenen35. These mice were bred with transgenic mice containing Cre recombinase driven by the adi-
ponectin promoter purchased from Jackson Laboratories (stock number 010803, Bar Harbor, ME) to create the 
following genotypes: PU.1 fl/fl (control), PU.1 fl/fl-AdipoqCre (PU.1 AKO). All experiments were approved by 
and conducted in accordance with the Animal Care Program at the University of California, San Diego.
GTTs, ITTs, and hyperinsulinemic-euglycemic clamp study. Male fl/fl and PU.1 AKO mice were fed 
60% high fat diet (HFD, D12492, Research Diets, New Brunswick, NJ). Glucose and insulin tolerance tests were 
performed on mice after 6 h fasting. Mice were injected IP with dextrose (1 g/kg, Hospira, Lake Forest, IL) for 
GTTs or with insulin (0.35 U/kg, Novolin R, Novo-Nordisk, Princeton, NJ) for ITTs. Blood was drawn at 0, 15, 
30, 60, 90, and 120 min after injection for blood glucose determination using an Easy Step blood glucose monitor 
(Home Aid Diagnostics Inc, FL). Clamp studies were performed as previously described36,37 after 12 weeks of 
HFD feeding. Briefly, dual catheters (catalog no. MRE025, Braintree Scientific, Braintree, MA) were implanted 
in the right jugular vein, tunneled subcutaneously, and exteriorized at the back of the neck. Mice were allowed 
to recover for 4–5 days prior to the clamp procedure. After 6 h fasting, mice were placed in a Lucite restrainer 
(Braintree Scientific) and blood glucose was measured via tail nick. The experiment began with a constant infu-
sion (5 μCi/hr) of D-[3-3H] glucose (PerkinElmer NEN Radiochemicals, Boston, MA) via the jugular vein can-
nulae. After 90 minutes of tracer equilibration and basal blood sampling at −10 and 0 min, insulin (8 mU/kg/
min, Novo Nordisk) plus tracer (5 μCi/hr) and glucose (50% dextrose at variable rate, Hospira) infusions were 
initiated via the jugular vein cannulae simultaneously, with glucose infusion rate adjusted to reach a steady state 
blood glucose concentration (~120 min). Blood samples were collected via tail vein at −10, 0 (basal) 110, and 120 
(steady-state) min to determine glucose-specific activity and insulin and free fatty acid (FFA) levels. Steady-state 
conditions (120 mg/dl ± 10 mg/dl) were confirmed at the end of the clamp by ensuring that glucose infusion rate 
and plasma glucose levels maintained constant for 30 min. Tracer-determined hepatic glucose production (HGP) 
and glucose disposal rate (GDR) were calculated at the basal state and during the steady-state portions of the 
clamp by using the Steele equation for steady-state conditions38. At steady state, the rate of glucose disappearance 
(total GDR) is equal to the sum of the rate of endogenous glucose production (i.e., HGP) plus the exogenous 
(cold) GIR. The IS-GDR is equal to the total GDR minus the basal glucose turnover rate.
Gene expression. Epididymal adipose tissue (eWAT) was fractionated into adipocytes and the stromal 
vascular fraction (SVF) and liver fractionated into hepatocytes and non-parenchymal cells as described previ-
ously37,39. RNA extracted, converted to cDNA and relative expression analyzed by qPCR. Gene expression was 
calculated after normalization to the housekeeping gene Rplp0 using the ΔΔCt method. Gene expression was 
calculated relative to fl/fl (tissue) or control (cell culture) samples. Primer sequences used to measure gene expres-
sion are listed in Table S1 in the supplemental material.
SVC isolation and flow cytometry. Epididymal WAT was isolated from mice and minced in PBS contain-
ing 0.5% (w/v) FA-free BSA. Collagenase (C0130, Sigma) was added and tissue was incubated for 30 min at 37 °C 
while shaking. Cells were strained through a 100 μm cell strainer to remove tissue debris and separated by centrif-
ugation into adipocytes and SVCs. The pelleted SVC fraction was analyzed by FACS. SVCs in single-cell suspen-
sion were incubated with purified CD16/CD32 (BD Biosciences, San Diego, CA) to block non-specific antibody 
binding and with Zombie Aqua Fixable Viability Dye (BioLegend, San Diego, CA) to discriminate live cells from 
dead cells. Cells were incubated with the following antibody-fluorochrome conjugates for extracellular marker 
recognition: CD11b-FITC (M170) and CD11c-APC (HL3) (from BD Biosciences, San Jose, CA), F4/80-PE-Cy7 
(BM8, from eBiosciences, San Diego, CA).
Primary adipocyte culture. Primary adipocytes isolated from eWAT were cultured as previously described36. 
Briefly, the adipocyte layer was washed in Krebs-Ringer solution (0.12M sodium chloride, 4.7 mM potassium chlo-
ride, 2.5 mM calcium chloride, 1.2 mM magnesium sulfate, 1.2 mM potassium phosphate, and 20 mM HEPES, pH 7.4, 
supplemented with 1% FA-free BSA, 200 nM adenosine, and 2 mM glucose) then resuspended in DMEM medium 
containing 4.5 mM glucose and supplemented with 4% FA-free BSA, 100 nM adenosine, 10 mM HEPES, Penicillin, and 
streptomycin. The cells were cultured at 37 °C, 5% CO2 and conditioned medium was collected after 24 h.
Glucose uptake assays in primary adipocytes. Glucose uptake was measured after 24 h serum starvation in 
primary adipocytes40. Briefly, cells were equilibrated in Hepes-Salt buffer (10 mM Hepes, 40 mM potassium chloride, 
125 mM sodium chloride, 0.85 mM potassium phosphate monobasic, 1.25 mM sodium phosphate dibasic, 1 mM mag-
nesium chloride, 1 mM calcium chloride, 0.1% fatty acid-free BSA) for 2 h for glucose starvation, treated with or with-
out 100 nM insulin for 20 minutes followed by 2 μCi 3H-2-deoxy-D-glucose for 10 minutes at 37 °C. The glucose uptake 
was halted by washing with ice cold PBS. The cells were lysed with sodium hydroxide, protein concentration measured, 
samples were neutralized with hydrochloric acid, and samples were counted in scintillation fluid.
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Histology and immunohistochemistry. Paraffin-embedded WAT and liver tissue sections were stained 
with hematoxylin and eosin (H&E). Anti-F4/80 antibody (Abcam, Cambridge, MA) was used for immunohis-
tochemistry staining by the UCSD Histology and Immunohistochemistry Core. For eWAT adipocyte sizing, at 
least 100 cells from 3–5 images for each section were measured using CellProfiler software (v 2.1.1), using the 
Adipocyte H&E Cell Profiler Pipeline. The cell diameter was calculated for each cell and measured 100–300 cells 
per slide (3–5 fields). Pixel area per cell was converted to pixel diameter and subsequently converted to μm. Cells 
were then binned by diameter into 10 μm groups41.
In vivo monocyte tracking assay. In vivo monocyte tracking was performed as previously described42. 
Briefly, leukocytes pooled from 10-wk-old male C57BL/6 mice bled from the retro-orbital sinus were subjected 
to red blood cell lysis. Isolated monocytes were washed in RPMI-1640 medium, counted, and suspended in 2 ml 
diluent solution C included in the PKH26 labeling kit (Sigma, St. Louis, MO) per 5 × 106 to 10 × 106 cells. 2 ml 
PKH26 diluted to 2 × 10−3 mol/L in diluent solution C was added to the monocytes and mixed. Monocytes were 
incubated in the PKH26-containing solution for 10 min in the dark at room temperature. Staining was halted 
by the addition of medium containing 10% FBS and monocytes washed in PBS and resuspended in serum con-
taining medium. PKH26-labeled monocytes were counted and 1 × 106 cells were suspended in 0.2 ml PBS and 
injected retro-orbitally into each recipient mouse (HFD-fed fl/fl or PU.1 AKO mice). SVCs were isolated from 
recipient mice 5 days post injection, eWAT, stained, and analyzed by FACS.
In vitro IP-macrophage chemotaxis assay. Thioglycollate-elicited IP-macrophages were isolated 
from 8–10-wk-old male C57BL/6 mice and cultured for 3 days, as previously described43. For migration assays, 
macrophages were place in the upper chamber of an 8 μm polycarbonate transwell filter (24 well plate), while 
medium containing conditioned medium, diluted 1:200, from PU.1 AKO or fl/fl primary HFD adipocytes cul-
tured for 24 h was placed in the lower chamber. After 3 h migration, cells were formalin-fixed and stained with 4′, 
6-diamidino-2-phenylindole and observed. Successful macrophage migration was determined by macrophage 
migrating to the opposite side of the filter.
3T3-L1 in vitro studies. Cells were plated in 24 well plates with 1 × 105 cells per well and treated for 48 h 
with 10 ng/ml TNF-a (Cell Signaling Technology, Danvers, MA) 1 d post-transfection.
Western blots. Tissues were lysed in RIPA buffer, and concentration of protein lysates were measured using 
BioRad Protein Assay. Equal concentrations of protein were loaded and electrophoresed on 4–15% TGX Criterion 
gels (BioRad), transferred to PVDF membranes, and immunoblotted. Antibodies used were PU.1 (2266S, rabbit 
polyclonal, Cell Signaling), pSer 473 AKT (rabbit monoclonal, Cell Signaling), panAKT (mouse monoclonal, Cell 
Signaling), pSer 273 PPARg (bs-4888R, rabbit polyclonal, Bioss), PPARg (sc-7196, rabbit polyclonal, Santa Cruz), 
HSP 90α/β (sc-7947, rabbit polyclonal, Santa Cruz), Phospho-p44/42 MAPK (ERK1/2)(Thr202/Tyr204)(9101, 
Cell signaling), p-Cdk5(ser159), sc-12919, Santa Cruz), followed by appropriate HRP-linked secondary antibody. 
SuperSignal West Pico Chemiluminescent substrate (Thermo Scientific) was used to develop blots. Band intensity 
was measured using NIH ImageJ software.
Determining adipocyte cell size. Adipose tissue was dissected, fixed, and embedded in paraffin, sectioned 
and stained with H&E. Images were captured using a NanoZoomer slide scanner system with NanoZoomer 
Digital Pathology software (Hamamatsu). Images were analyzed and cell diameter measured using ImageJ soft-
ware and presented as number of cells in each cell size category.
Plasma measurements. Plasma leptin, resistin, and PAI-1 were measured using a Milliplex Multiplex assay 
(Millipore, Billerica, MA). Plasma adiponectin was measured using ELISA (Millipore), plasma insulin was measured by 
ELISA (ALPCO). Plasma triglycerides and free fatty acids were measured enzymatically (NEFA C, Wako Chemicals).
LTB4 measurement. LTB4 was measured in eWAT from fl/fl and PU.1 AKO mice after 14 wk HFD as pre-
viously described44.
Statistical analysis. For two-group comparisons, data were analyzed by Student’s t-test. For two-way com-
parisons over time (GTT and ITT), data were analyzed by 2-way ANOVA for repeated measures with Sidak 
post-hoc test. For comparisons of more than two groups, data were analyzed by two-way ANOVA followed by 
Tukey’s post-hoc test. For multiple two-group comparisons, data were analyzed by multiple t-test followed by the 
Holm-Sidak method to correct for multiple comparisons. P < 0.05 was considered statistically significant. Using 
GraphPad Prism 6.0 software (San Diego, CA).
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